# Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects

> **NCT03001115** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 17 (actual)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03001115
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001115, "Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03001115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*